Biotinylated Human HLA-A*02:01&B2M&gp100 (YLEPGPVTA) Complex Protein (Monomer, MALS verified)

Glycoprotein 100, is also well known as gp100 and Melanocyte protein PMEL. This antigen is a melanocyte-specific type I transmembrane glycoprotein and composed of 661 amino acids. Glycoprotein 100 is related to the tumor regression in metastatic melanoma patients after adoptive therapy, by which its epitopes being recognized by tumor lymphocytes and T-cells. The gp100280–288 (YLEPGPVTA) was originally shown to be recognized by HLA-A*0201 tumor-infiltrating lymphocytes from melanoma patients, and therefore it is widely been studied in TCR -T studies. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100.

Biotinylated Human HLA-A*02:01&B2M&gp100 (YLEPGPVTA) Complex Protein is produced by co-expression of HLA and B2M loaded with gp100 peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 36.0 kDa and 13.7 kDa. The protein migrates as 36-40 kDa, 17 kDa and 15 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Immobilized Biotinylated Human HLA-A*02:01&B2M&gp100 (YLEPGPVTA) Complex Protein (Cat. No. HLG-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-4 ng/mL (QC tested).